Complicated Urinary Tract Infections (cUTIs) Market Size, Epidemiology Trends, Treatment, and Forecast to 2035

According to the IMARC Group, the complicated urinary tract infections (cUTIs) market reached a value of USD 1,689.6 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,030.4 Million by 2035, exhibiting a growth rate (CAGR) of 5.44% during 2025-2035. This can be attributed to the increasing application of targeted gene therapies, given their premise of specifically addressing the genetic vulnerabilities of pathogenic bacteria.

Complicated urinary tract infections (cUTIs) are a subset of UTIs that usually occur in patients with functional or structural abnormalities of the urinary system or in those with underlying health issues, making treatment more challenging. The complicated urinary tract infections (cUTIs) market is experiencing substantial growth driven by the rising prevalence of antibiotic-resistant bacterial strains, significantly increasing the demand for advanced treatment options.

Besides this, the aging population, which is more susceptible to the condition due to weakened immune systems and comorbidities like diabetes and benign prostatic hyperplasia, is contributing to the complicated urinary tract infections (cUTIs) market expansion. Advancements in diagnostic technologies, including rapid molecular assays and next-generation sequencing, are enabling earlier and more precise detection of causative pathogens, leading to personalized therapeutic plans and better patient outcomes. Moreover, pharmaceutical companies are actively investing in the development of novel antibiotics and non-antibiotic therapies to address the growing challenge of resistance and improve efficacy in difficult-to-treat infections, thereby catalyzing the complicated urinary tract infections (cUTIs) market growth.

Increasing awareness about the severe complications of untreated illnesses, such as kidney damage and sepsis, is driving patients to seek timely medical intervention. Additionally, the integration of telemedicine and digital health solutions is also enhancing access to diagnosis and treatment, particularly in remote areas, further stimulating the complicated urinary tract infections (cUTIs) market expansion. Government initiatives to support antimicrobial stewardship and the prudent use of antibiotics are shaping market dynamics. Furthermore, the emergence of targeted therapies based on genetic vulnerabilities of pathogenic bacteria is expected to bolster the complicated urinary tract infections (cUTIs) market growth in the coming years.

Request for a sample of this report: https://www.imarcgroup.com/complicated-urinary-tract-infections-market/requestsample

Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Complicated Urinary Tract Infections (cUTIs) Market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Complicated Urinary Tract Infections (cUTIs) Market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current Complicated Urinary Tract Infections (cUTIs) Market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the Complicated Urinary Tract Infections (cUTIs) Market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Merck Sharp and Dohme
2. Cipla Therapeutics
3. Shionogi
4. Merck Sharp & Dohme
5. Melinta Therapeutics
6. GSK/Spero Therapeutics
7. Wockhardt
8. Allecra Therapeutics
9. VenatoRx Pharmaceuticals
10. Nabriva Therapeutics

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=13748&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

IMARC Group Offers Other Reports:

Esophageal Cancer Market https://www.imarcgroup.com/esophageal-cancer-market

Diabetic neuropathy Market https://www.imarcgroup.com/diabetic-neuropathy-market

Periodontal Disease Market https://www.imarcgroup.com/periodontal-disease-market

Multiple Myeloma Market https://www.imarcgroup.com/relapsed-refractory-multiple-myeloma-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.